Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-31 2024-12-31 7 2024-01-01 No description of principal activity true false 7 true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07588847 2024-01-01 2024-12-31 07588847 2023-01-01 2023-12-31 07588847 2024-12-31 07588847 2023-12-31 07588847 c:Director1 2024-01-01 2024-12-31 07588847 d:PlantMachinery 2024-01-01 2024-12-31 07588847 d:PlantMachinery 2024-12-31 07588847 d:PlantMachinery 2023-12-31 07588847 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07588847 d:FurnitureFittings 2024-01-01 2024-12-31 07588847 d:FurnitureFittings 2024-12-31 07588847 d:FurnitureFittings 2023-12-31 07588847 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07588847 d:OfficeEquipment 2024-01-01 2024-12-31 07588847 d:OfficeEquipment 2024-12-31 07588847 d:OfficeEquipment 2023-12-31 07588847 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07588847 d:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 07588847 d:OtherPropertyPlantEquipment 2024-12-31 07588847 d:OtherPropertyPlantEquipment 2023-12-31 07588847 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07588847 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 07588847 d:CurrentFinancialInstruments 2024-12-31 07588847 d:CurrentFinancialInstruments 2023-12-31 07588847 d:Non-currentFinancialInstruments 2024-12-31 07588847 d:Non-currentFinancialInstruments 2023-12-31 07588847 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 07588847 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 07588847 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 07588847 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 07588847 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-12-31 07588847 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2023-12-31 07588847 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-12-31 07588847 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-12-31 07588847 d:ShareCapital 2024-12-31 07588847 d:ShareCapital 2023-12-31 07588847 d:RetainedEarningsAccumulatedLosses 2024-12-31 07588847 d:RetainedEarningsAccumulatedLosses 2023-12-31 07588847 c:OrdinaryShareClass1 2024-01-01 2024-12-31 07588847 c:OrdinaryShareClass1 2024-12-31 07588847 c:OrdinaryShareClass1 2023-12-31 07588847 c:FRS102 2024-01-01 2024-12-31 07588847 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 07588847 c:FullAccounts 2024-01-01 2024-12-31 07588847 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 07588847 e:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 07588847 MAGNA LABORATORIES LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 DECEMBER 2024
MAGNA LABORATORIES LIMITED REGISTERED NUMBER: 07588847 STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2024
|  | 2024 |  | 2023
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Tangible assets | 4 |  | 64,017 |  | 104,109
|  |  | 64,017 |  | 104,109
Current assets |  |  |  |  |
Stocks |  | 3,725 |  | 3,995 |
Debtors: amounts falling due within one year | 5 | 446,741 |  | 306,929 |
Cash at bank and in hand |  | 6,341 |  | 2,649 |
|  | 456,807 |  | 313,573 |
Creditors: amounts falling due within one year | 6 | (369,032) |  | (412,426) |
Net current assets/(liabilities) |  |  | 87,775 |  | (98,853)
Total assets less current liabilities |  |  | 151,792 |  | 5,256
Creditors: amounts falling due after more than one year | 7 |  | (5,271) |  | (15,639)
Net assets/(liabilities) |  |  | 146,521 |  | (10,383)
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 3 |  | 3
Profit and loss account |  |  | 146,518 |  | (10,386)
|  |  | 146,521 |  | (10,383)
Page 1
MAGNA LABORATORIES LIMITED REGISTERED NUMBER: 07588847 STATEMENT OF FINANCIAL POSITION (CONTINUED) AS AT 31 DECEMBER 2024 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 4 August 2025.
W M van Rijn
Director
The notes on pages 3 to 7 form part of these financial statements. Page 2
MAGNA LABORATORIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 1.Accounting policies
| 1.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The presentational currency of the Company is GBP. The following principal accounting policies have been applied:
| 1.2 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 1.3 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 1.4 | Borrowing costs
All borrowing costs are recognised in profit or loss in the year in which they are incurred.
| 1.5 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds. Page 3
MAGNA LABORATORIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 1.Accounting policies (continued)
| 1.6 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, as shown below. Depreciation is provided on the following basis:
|  |  |  | Plant and machinery | - | 10/25% straight line/reducing balance
|  |  |  | Fixtures and fittings | - | 20% reducing balance
|  |  |  | Office equipment | - | 33% reducing balance
|  |  |  | Other fixed assets | - | 20% straight line
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 1.7 | Stocks
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads. At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.
| 1.8 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 1.9 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 1.10 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Page 4
MAGNA LABORATORIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
2. | General information
Magna Laboratories Limited is a private company, limited by shares and incorporated in England and Wales. Its registered number is: 07588847 Its Registered Office is: Unit 5 Chase Industrial Estate Ross-On-Wye Herefordshire HR9 5WA
3. | Employees
| The average monthly number of employees, including directors, during the year was 7 (2023 - 7).
4. | Tangible fixed assets
|  | Plant and machinery | Fixtures and fittings | Office equipment | Other fixed assets | Total
|  | £ | £ | £ | £ | £
| Cost or valuation |  |  |  |  |
| At 1 January 2024 | 449,962 | 36,320 | 86,190 | 145,980 | 718,452
| Additions | - | - | 2,972 | - | 2,972
| At 31 December 2024 | 449,962 | 36,320 | 89,162 | 145,980 | 721,424
| Depreciation |  |  |  |  |
| At 1 January 2024 | 379,994 | 31,631 | 62,537 | 140,181 | 614,343
| Charge for the year on owned assets | 31,408 | 938 | 8,786 | 1,933 | 43,065
| At 31 December 2024 | 411,402 | 32,569 | 71,323 | 142,114 | 657,408
| Net book value |  |  |  |  |
| At 31 December 2024 | 38,560 | 3,751 | 17,839 | 3,866 | 64,016
| At 31 December 2023 | 69,968 | 4,689 | 23,653 | 5,799 | 104,109
Page 5
MAGNA LABORATORIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
5. | Debtors
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade debtors | 372,041 | 295,147
| Amounts owed by group undertakings | 56,438 | -
| Other debtors | - | 380
| Prepayments and accrued income | 18,262 | 11,402
|  | 446,741 | 306,929
6. | Creditors: Amounts falling due within one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Bank loans | 10,398 | 10,148
| Trade creditors | 20,155 | 8,956
| Other taxation and social security | 12,375 | -
| Other creditors | 321,404 | 388,805
| Accruals and deferred income | 4,700 | 4,517
|  | 369,032 | 412,426
7. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Bank loans | 5,271 | 15,639
|  | 5,271 | 15,639
Page 6
MAGNA LABORATORIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
8. | Loans
| Analysis of the maturity of loans is given below:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Amounts falling due within one year |  |
| Bank loans | 10,398 | 10,148
|  | 10,398 | 10,148
| Amounts falling due 1-2 years |  |
| Bank loans | 5,270 | 10,398
|  | 5,270 | 10,398
| Amounts falling due 2-5 years |  |
| Bank loans | - | 5,239
|  | - | 5,239
|  | 15,668 | 25,785
9. | Share capital
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
|  | Authorised |  |
|  | 1,000 (2023 - 1,000) Ordinary shares of £1.00 each | 1,000 | 1,000
|  | Allotted, called up and fully paid |  |
|  | 3 (2023 - 3) Ordinary shares of £1.00 each | 3 | 3
10. | Controlling party
The controlling party of the company is Leyden Holding BV, a company registered in the Netherlands. The ultimate controlling parties are W M van Rijn and M Helthuis-Jollie by virtue of their shareholdings in Leyden Pharmaceutical BV.
Page 7